We evaluated the in-vitro activity of plazomicin against other aminoglycosides in 122 clinical CRE isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in-vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from CLSI to USCAST breakpoints.

中文翻译：

---

在耐碳青霉烯的肠杆菌科细菌中，吡唑米星的体外活性与其他临床相关的氨基糖苷相比。

我们使用几种临床敏感性断点评估了122种临床CRE菌株中吡唑米星对其他氨基糖苷的体外活性。Plazomicin具有出色的体外活性，整体敏感性为98％。其次是阿米卡星，总敏感性为86％。从CLSI切换到USCAST断点时，下降到55％。